China-based bio-ingredient solution provider, Bon Natural Life Limited (BON) has unveiled a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar, which is gearing up for release.
The company has engineered a food-derived postbiotic formula for glycemic management, slated to hit retail shelves in the near term. When taken 10-30 minutes before meals, this breakthrough product delivers targeted control over post-meal glucose spikes, cutting blood sugar surges by 15-30% within the critical 1-3 hour window after eating-proven through rigorous testing.
Early data from BON showed its efficacy not only rivals but outperforms leading products already dominating the market. Beyond its precision, the formula boasts a unique edge: It’s food-safe, easy to use, and designed for seamless integration into daily routines – key factors driving high user adherence. With these advantages, the solution is poised to disrupt the post-meal blood sugar control sector and capture significant market share.
Yongwei Hu, Chairman of BON said, “Backed by a robust IP strategy, the Company is aggressively pursuing global patent protection. Over the next 2 years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal.”
